Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party

Allo-SCT is a valid treatment option in relapsed/refractory PTCL where targeted therapies still play a limited role. Patients with AITL survived significantly better than patients with PTCL NOS or ALK-negative ALCL following a significantly lower RI, also when comparing CR/complete metabolic response (CMR) and PR patients separately. Higher age and non-CR at allo-SCT are associated with worse outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Hematology & Oncology
Published
2026-02-21
DOI
https://doi.org/10.1186/s13045-026-01783-w
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party

E. Wagner-Drouet, A. Sureda, N. Schmitz, Gerald Wulf et al.
Journal of Hematology & Oncology
Lymphoma Diagnosis and Treatment
article

Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party

E. Wagner-Drouet, A. Sureda, N. Schmitz, Gerald Wulf, Francesca Kinsella, Philipp Berning, Maud Ngoya, R. devillier, Thomas A. Schroeder, Frank Kroschinsky, Veronika Válková, Evgenii Shumilov, G. Olesen, Georg Lenz, Marco Herling, Lucía Lopez-Corral, Peter Dreger, M. Mohty, Ali Bazarbachi, F Ayuk, Flore Sicre de Fontbrune, Arain Laurence, Matthias Stelljes, Robert Zeiser
article en

Abstract

Allo-SCT is a valid treatment option in relapsed/refractory PTCL where targeted therapies still play a limited role. Patients with AITL survived significantly better than patients with PTCL NOS or ALK-negative ALCL following a significantly lower RI, also when comparing CR/complete metabolic response (CMR) and PR patients separately. Higher age and non-CR at allo-SCT are associated with worse outcomes.

Journal of Hematology & OncologyVol. 19(1)
University College Hospital (GB), Memorial Sloan Kettering Cancer Center (US), Universität Hamburg (DE), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), Queen Elizabeth Hospital Birmingham (GB), University Medical Center Freiburg (DE), University Hospital Heidelberg (DE), Aarhus University Hospital (DK), Sorbonne Université (FR), Institut d'Investigació Biomédica de Bellvitge (ES), University Medical Center of the Johannes Gutenberg University Mainz (DE), Institute of Haematology and Blood Transfusion (CZ), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Saint-Antoine (FR), University Hospital Münster (DE), Institut Català d'Oncologia (ES), University Medical Center Hamburg-Eppendorf (DE), Essen University Hospital (DE), Hôpital Cardiologique du Haut-Lévêque (FR), University Hospital Leipzig (DE), Hôtel-Dieu de Paris (FR), Instituto de Investigación Biomédica de Salamanca (ES), Hôpital Saint-Louis (FR), Institut Paoli-Calmettes (FR), University Hospital Carl Gustav Carus (DE), European Society for Blood and Marrow Transplantation (FR), University College London (GB), Universitat de Barcelona (ES), University of Göttingen (DE), Technische Universität Dresden (DE), American University of Beirut (LB)
Openalex Percentile: Top 48%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.